(NASDAQ: CABA) Cabaletta Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Cabaletta Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CABA's revenue for 2027 to be $9,491,297,164, with the lowest CABA revenue forecast at $9,491,297,164, and the highest CABA revenue forecast at $9,491,297,164. On average, 2 Wall Street analysts forecast CABA's revenue for 2028 to be $15,661,373,051, with the lowest CABA revenue forecast at $1,704,818,688, and the highest CABA revenue forecast at $29,617,927,413.
In 2029, CABA is forecast to generate $33,621,564,652 in revenue, with the lowest revenue forecast at $12,295,210,994 and the highest revenue forecast at $54,947,918,311.